高濃度血小板血漿製劑個體差異之分析方法

專利類型

發明

專利國別 (專利申請國家)

中華民國

專利申請案號

106128496

專利證號

I 680184

專利獲證名稱

高濃度血小板血漿製劑個體差異之分析方法

專利所屬機關 (申請機關)

長庚大學

獲證日期

2019/12/21

技術說明

因組織細胞生長不易，為了增進臨床效果，除了手術中縫合固定的強度外，需要使用各種方法促進肌腱在骨骼附著端之生長，而人體的血小板內有多種生長因子與肌腱及骨膜生長癒合有關，因此在近年來被廣泛研究。但是，目前高濃度血小板血漿(PRP)療法之成效不一，而PRP之處理方法及注射療程亦沒有標準程序，目前只是依賴醫師之臨床經驗給予病人評估是否進行PRP療法。因此，本計劃建立一個PRP療法評估服務，開發高通量及自動化之細胞共同培養組織細胞及PRP之平台，藉病人手術後之組織檢體分離之細胞與病人自身PRP進行體外培養，達至實時探討組織細胞與PRP共同培養下之增生情況，給予醫師及病人科學數據再評估PRP療法之成效及療程。 High incidence of recurrent tendon defect was occurred after the surgery of repair construct. That indicates the biological tendon-bone healing is limited although high strength of mechanical support is applied. Recently, the platelet-rich plasma (PRP) prolotherapy was proposed because the PRP can derive a lot of growth factors for enhancing tendon-bone healing. However, the efficacy may be influenced by individuals. Moreover, the optimal concentration of PRP and standardization in the preparation of PRP are yet to be determined. Currently, the decision of taking PRP prolotherapy is only based on the clinical advices from physicians. In this project, a high throughput and automatic in vitro screening platform is developed for co-culturing cells isolated from patient's tissue and autologous PRP. The proliferation of the cells is investigated under the stimulation of PRP. This provides useful information to physicians for the determination of the efficacy and efficiency of the PRP prolotherapy for every individual patients.

備註

連絡單位 (專責單位/部門名稱)

技術移轉中心

連絡電話

03-2118800轉3201

網址